PACIFIC NEUROSCIENCE INSTITUTE℠

JOHN WAYNE CANCER INSTITUTE
at Providence Saint John's Health Center

CLINICAL TRIAL ANNOUNCEMENT

Phase II Trial to Evaluate **Pemigatinib** in Patients with **Solid Tumor Malignancy**

For more information, contact the Neuro-Oncology Clinical Trial Team at:
Neuro.Oncology@jwci.org
310-829-8265

Clinical Trial Investigators
Garni Barkhoudarian, MD
Jose Carrillo, MD
Daniel Kelly, MD
Santosh Kesari, MD, PhD
Steven O'Day, MD
Marlon Garzo Saria, PhD, RN
Naveed Wagle, MD

Clinical Trial Team

Annie Heng, RN, BSN
Annie.Heng@providence.org
310-582-7457

Hanh Nguyen, CRA
NguyenThuyH@jwci.org
310-582-7434

Shelly Trujillo, CRA
Shelly.Trujillo@providence.org
310-582-7097

Ashley Archer, CRA
ArcherA@jwci.org
310-582-7460

Sponsor
Incyte Corportation

Saint John's Health Center
PROVIDENCE Health & Services

Official Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib which will be administered orally everyday.

Pemigatinib is an inhibitor of the FGFR family of receptor tyrosine kinases that is proposed for the treatment of solid tumor malignancies with an activating FGFR mutation or translocation. FGFR contributes to the development of malignancies by promoting tumor cell proliferation, survival, migration, and angiogenesis.

Preclinical and clinical data support the use of FGFR inhibitors in FGFR altered cell lines and tumors derived from a variety of cancer types. For this reason, administering pemigatinib will allow consistent inhibition of the aberrant FGFG receptor in this population.

Key Inclusion Criteria:

- Histologically or cytologically confirmed tumor malignancy that is advanced or metastatic, or is surgically unresectable.
- Age ≥18.
- Documentation of an FGFR1-3 gene mutation or translocation
- Baseline archival tumor specimen (if less than 12 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain specimen

Key Exclusion Criteria:

- Prior receipt of a selective FGFR inhibitor
- Current evidence of clinically significant corneal or retinal disorder
- Untreated brain/CNS metastases or CNS metastases that have progressed. Note: Participants with progressing primary brain tumors are allowed if they have no new neurological symptoms